EDSA net incomeQ3 2026-$5.41M
EDSA net income was -$5.41M in fiscal Q3 2026 (ended Jun 30, 2026), compared with -$1.75M a year earlier. For the full fiscal 2025 it was -$7.19M, compared with -$6.17M in fiscal 2024.
Edesa Biotech Inc. (EDSA) financials
For the twelve months ended Jun 30, 2026, Edesa Biotech Inc. reported -$14.10M of net income.
- Net income, TTM
- -$14.10M
- Cash
- $10.30M
- Market cap
- $33.6M
FY2015FY2022
FY2015FY2025
FY2015FY2023
EDSA revenue and earnings growth
Income statement
| Line item | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Dec 31, 2018 | Sep 30, 2017 | Sep 30, 2016 | Sep 30, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | $780.0K | $10.34M | $328.8K | $0 | $228.3K | $1.27M | $758.7K |
| Cost of revenue | - | - | - | - | $0 | $17.6K | $0 | $250.0K | $818.6K | $580.8K |
| Gross profit | - | - | - | - | $10.34M | $311.2K | $0 | -$21.8K | $453.1K | $177.9K |
| Research and development | $3.67M | $2.88M | $4.79M | $13.34M | $17.95M | $3.33M | $1.08M | $1.97M | $1.73M | $1.03M |
| Selling, general and admin | $4.24M | $4.13M | $4.43M | $5.04M | $5.73M | $3.38M | $543.2K | $2.94M | $3.32M | $3.23M |
| Operating income | -$7.91M | -$7.01M | -$9.22M | -$18.37M | -$23.68M | -$6.40M | -$1.62M | -$5.22M | -$4.91M | -$4.34M |
| Pre-tax income | -$7.18M | -$6.17M | -$8.37M | -$17.55M | -$13.34M | - | - | -$5.03M | -$5.02M | -$2.81M |
| Income tax | $800 | $800 | $800 | $800 | $800 | $800 | $0 | $800 | $7.2K | $36.8K |
| Net income | -$7.19M | -$6.17M | -$8.37M | -$17.55M | -$13.34M | -$6.36M | -$1.54M | -$5.03M | -$5.03M | -$2.84M |
| EPS, basic | -$1.27 | -$1.93 | -$2.93 | - | -$1.10 | -$0.74 | -$0.47 | -$3.44 | -$3.99 | -$2.52 |
| EPS, diluted | - | - | - | - | -$1.10 | -$0.74 | -$0.47 | -$3.44 | -$3.99 | -$2.52 |
| Diluted shares | - | - | - | - | 12.1M | 8.6M | 3.2M | 1.5M | 1.3M | 1.1M |
Balance sheet
| Line item | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Dec 31, 2018 | Sep 30, 2017 | Sep 30, 2016 | Sep 30, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $10.79M | $1.04M | $5.36M | $7.09M | $7.84M | $7.21M | $3.37M | $4.57M | $7.42M | $3.96M |
| Short-term investments | - | - | - | - | - | - | $1.60M | $1.99M | $3.99M | $5.02M |
| Receivables | - | - | - | - | $3.30M | $87.4K | $7.3K | $1.3K | $85.8K | $157.6K |
| Inventory | - | - | - | - | - | - | $0 | $68.1K | $249.4K | $557.3K |
| Current assets | $11.51M | $1.68M | $6.44M | $9.09M | $12.09M | $8.10M | $3.39M | $6.76M | $12.10M | $9.87M |
| Total assets | $13.53M | $3.81M | $8.89M | $11.58M | $14.58M | $10.76M | $3.40M | $7.72M | $12.94M | $10.39M |
| Current liabilities | $1.08M | $1.83M | $1.82M | $2.14M | $1.46M | $1.53M | $183.8K | $320.9K | $623.6K | $2.38M |
| Total liabilities | - | $1.83M | $1.84M | $2.18M | $1.53M | $1.65M | $183.8K | - | - | $2.38M |
| Shareholders' equity | $12.45M | $1.98M | $7.05M | $9.39M | $13.06M | $6.63M | $3.21M | $7.40M | $12.31M | $8.01M |
Cash flow
| Line item | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Dec 31, 2018 | Sep 30, 2017 | Sep 30, 2016 | Sep 30, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.32M | -$4.89M | -$6.64M | -$12.28M | -$13.66M | -$4.99M | -$1.29M | -$4.70M | -$4.51M | -$4.41M |
| Capital expenditures | - | - | $0 | $5.7K | $6.1K | $4.9K | $6.9K | $302.7K | $402.3K | $274.6K |
| Free cash flow | - | - | -$6.64M | -$12.28M | -$13.67M | -$4.99M | -$1.30M | -$5.00M | -$4.91M | -$4.69M |
| Investing cash flow | - | - | $0 | -$5.7K | -$6.1K | $19.1K | -$6.9K | $1.69M | $557.4K | $122.5K |
| Financing cash flow | $17.03M | $592.0K | $4.83M | $11.63M | $14.17M | $7.09M | - | $0 | $7.31M | $106.8K |
| Stock-based compensation | $729.6K | $537.5K | $1.25M | $2.26M | $3.20M | $598.4K | $81.3K | $115.5K | $259.4K | $267.2K |
| Depreciation and amortization | $119.3K | $186.0K | $183.5K | $118.2K | $118.8K | $57.6K | $1.7K | $179.0K | $149.6K | $159.5K |
Key ratios
| Line item | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Dec 31, 2018 | Sep 30, 2017 | Sep 30, 2016 | Sep 30, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | -92.5% | 3044.8% | - | -100.0% | -82.0% | 67.6% | 103.9% |
| Gross margin | - | - | - | - | 100.0% | 94.6% | - | -9.5% | 35.6% | 23.4% |
| Operating margin | - | - | - | -2355.2% | -229.0% | -1946.7% | - | -2288.6% | -386.0% | -571.9% |
| Net margin | - | - | - | -2249.9% | -129.0% | -1935.3% | - | -2203.7% | -395.2% | -374.7% |
| Free cash flow margin | - | - | - | -1575.0% | -132.2% | -1518.0% | - | -2191.3% | -385.9% | -617.8% |
| Return on equity | -57.7% | -311.4% | -118.8% | -186.9% | -102.2% | -96.0% | -47.8% | -68.0% | -40.8% | -35.5% |
| Return on assets | -53.1% | -161.8% | -94.2% | -151.6% | -91.5% | -59.1% | -45.2% | -65.2% | -38.8% | -27.4% |
| Current ratio | 10.67 | 0.91 | 3.53 | 4.25 | 8.29 | 5.30 | 18.45 | 21.06 | 19.40 | 4.14 |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $3.96M | $2.77M | $1.12M | $1.23M | $939.1K | $484.3K | $1.02M | $103.9K | $897.3K | $1.18M | $704.5K | $953.4K |
| Selling, general and admin | $1.56M | $1.53M | $1.22M | $1.24M | $964.7K | $1.15M | $878.9K | $900.5K | $1.04M | $1.04M | $1.15M | $1.42M |
| Operating income | -$5.52M | -$4.30M | -$2.34M | -$2.47M | -$1.90M | -$1.64M | -$1.90M | -$1.00M | -$1.93M | -$2.22M | -$1.86M | -$2.37M |
| Pre-tax income | -$5.41M | -$4.22M | -$2.25M | -$2.23M | -$1.75M | -$1.59M | -$1.62M | -$962.1K | -$1.67M | -$1.86M | -$1.68M | -$1.72M |
| Income tax | $0 | $800 | $0 | $0 | $0 | $800 | $0 | $0 | $0 | $800 | $0 | $0 |
| Net income | -$5.41M | -$4.22M | -$2.25M | -$2.23M | -$1.75M | -$1.59M | -$1.62M | -$962.1K | -$1.67M | -$1.86M | -$1.68M | -$1.72M |
| EPS, basic | -$0.60 | -$0.49 | -$0.28 | - | -$0.25 | -$0.30 | -$0.48 | - | -$0.52 | -$0.58 | -$0.54 | - |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $10.30M | $10.00M | $12.10M | $10.79M | $12.40M | $13.90M | $1.60M | $1.04M | $2.04M | $2.80M | $4.27M | $5.36M |
| Current assets | $10.78M | $10.42M | $12.72M | $11.51M | $12.76M | $14.39M | $2.07M | $1.68M | $3.05M | $4.24M | $5.42M | $6.44M |
| Total assets | $12.72M | $12.38M | $14.71M | $13.53M | $14.80M | $16.45M | $4.16M | $3.81M | $5.23M | $6.48M | $7.83M | $8.89M |
| Current liabilities | $3.91M | $2.19M | $756.2K | $1.08M | $672.7K | $914.7K | $1.90M | $1.83M | $2.36M | $2.15M | $1.99M | $1.82M |
| Total liabilities | - | - | - | - | - | - | - | $1.83M | $2.36M | $2.15M | $1.99M | $1.84M |
| Shareholders' equity | $8.81M | $10.20M | $13.95M | $12.45M | $14.13M | $15.54M | $2.26M | $1.98M | $2.87M | $4.32M | $5.84M | $7.05M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.08M | -$2.02M | -$2.09M | -$1.72M | -$1.70M | -$2.38M | -$1.52M | -$967.0K | -$856.5K | -$1.66M | -$1.41M | -$1.47M |
| Capital expenditures | - | - | - | - | - | - | - | - | - | - | - | $0 |
| Free cash flow | - | - | - | - | - | - | - | - | - | - | - | -$1.47M |
| Investing cash flow | - | - | - | - | - | - | - | - | - | - | $0 | $0 |
| Financing cash flow | $3.45M | -$9.0K | $3.36M | $186.5K | $0 | $14.77M | $2.07M | -$31.4K | $106.0K | $211.7K | $305.7K | $412.5K |
| Stock-based compensation | $547.5K | $484.9K | $399.9K | $404.4K | $177.4K | $66.7K | $81.2K | $93.9K | $109.5K | $149.7K | $184.4K | $517.1K |
| Depreciation and amortization | $25.6K | $25.9K | $25.5K | $25.9K | $25.8K | $24.5K | $43.1K | $44.2K | $51.4K | $45.4K | $45.0K | $46.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 2.76 | 4.76 | 16.82 | 10.67 | 18.97 | 15.73 | 1.09 | 0.91 | 1.29 | 1.97 | 2.73 | 3.53 |
Source: XBRL data Edesa Biotech Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-7, first reported May 7, 2018.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
EDSA peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| EDSA | - | - | -$14.10M | - | $33.6M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
EDSA FAQ
4 questionsIs EDSA profitable?
No. Edesa Biotech Inc. reported a net loss of $14.10M for the twelve months ended Jun 30, 2026.How much cash and debt does EDSA have?
Edesa Biotech Inc. reported $10.30M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did EDSA last report financial results?
The latest statements here come from Edesa Biotech Inc.'s 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.Where does this EDSA financial data come from?
Quantisnow builds these statements from the structured XBRL data Edesa Biotech Inc. files with the SEC. It is provided for information only and is not investment advice.